The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
The trial will enroll up to 42 patients in Finland across four cohorts
DiaMedica said it plans to launch the trial later in 2026
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
Alto met its enrollment goal with 83 patients across 13 US clinical sites
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
